Skip to content
JAZZJazz Pharmaceuticals plc

Earnings

When Jazz Pharmaceuticals plc reports, what it reported each quarter, and how the stock took the results.

67 quarters. Mar 31, 2010 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 23, after the close

Tue, Feb 23, 2027in 98 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 4

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$1.20B
Revenue, change from a year earlier: Q3 2026 +10.4%, Q2 2026 +15.5%, Q1 2026 +19.1%, Q4 2025 +10.1%
Net income
$203.45M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 +6.5%
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 +19.3%

Quarter by quarter

Q3 2026$1.24B+10.4% vs Q3 2025

Latest results

  1. Q3 2026Nov 2, 2026, after the closeThe release+7.1%by the close of Nov 3
    Revenue
    $1.24B
    +10.4%
    Net income
    -$483.40M
    N/M
    EPS
    -$7.48
    N/M
    Achieved total revenues of $1.2 billion in 3Q26, reflecting 10% year-over-year (YoY) growth.
  2. Q2 2026Aug 3, 2026, after the closeThe release+3.9%by the close of Aug 4
    Revenue
    $1.21B
    +15.5%
    Net income
    $192.80M
    N/M
    EPS
    $2.78
    N/M
  3. Q1 2026May 5, 2026, after the closeThe release+7.5%by the close of May 6
    Revenue
    $1.07B
    +19.1%
    Net income
    $293.10M
    N/M
    EPS
    $4.43
    N/M
  4. Q4 2025Feb 24, 2026, after the closeThe release+13.5%by the close of Feb 25
    Revenue
    $1.20B
    +10.1%
    Net income
    $203.45M
    +6.5%
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 2, 2026 · after-hoursNov 2, 202633 d10-Q$1.24B+10.4%-$7.48+7.1%
Q2 2026Jun 30, 2026Aug 3, 2026 · after-hoursAug 3, 202634 d10-Q$1.21B+15.5%$2.78+3.9%
Q1 2026Mar 31, 2026May 5, 2026 · after-hoursMay 5, 202635 d10-Q$1.07B+19.1%$4.43+7.5%
FY 2025
Q4 2025derivedDec 31, 2025Feb 24, 2026 · after-hoursFeb 24, 202655 d10-K$1.20B+10.1%—+13.5%
Q3 2025Sep 30, 2025Nov 5, 2025 · after-hoursNov 5, 202536 d10-Q$1.13B+6.7%$4.082.4%
Q2 2025Jun 30, 2025Aug 5, 2025 · after-hoursAug 6, 202537 d10-Q$1.05B+2.1%-$11.746.4%
Q1 2025Mar 31, 2025May 6, 2025 · after-hoursMay 7, 202537 d10-Q$897.80M−0.5%-$1.528.7%
FY 2024
Q4 2024derivedDec 31, 2024Feb 25, 2025 · after-hoursFeb 26, 202557 d10-K$1.09B+7.5%—+3.2%
Q3 2024Sep 30, 2024Nov 6, 2024 · after-hoursNov 7, 202438 d10-Q$1.05B+8.5%$3.42+6.8%
Q2 2024Jun 30, 2024Jul 31, 2024 · after-hoursAug 1, 202432 d10-Q$1.02B+6.9%$2.49—
Q1 2024Mar 31, 2024May 1, 2024 · after-hoursMay 2, 202432 d10-Q$901.98M+1.0%-$0.23—
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 2, 2026000057
10-QAug 3, 2026000045
10-QMay 5, 2026000025
10-KFeb 24, 2026000013
10-QNov 5, 2025000074
10-QAug 6, 2025000063
10-QMay 7, 2025000027
10-KFeb 26, 2025000011
10-QNov 7, 2024000086
10-QAug 1, 2024000068

Provenance

ProvenanceData status and checks

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR